The Competition Commission of India (CCI) has approved the acquisition of Kenvue Inc. by Kimberly-Clark Corporation, following a merger agreement dated November 2, 2025. This approval grants Kimberly-Clark sole control over Kenvue and allows them to proceed with further regulatory and corporate processes in India. The detailed order from CCI, outlining findings and conditions under competition law, is expected to be issued soon.

DTE Energy recently reported strong first-quarter 2026 results and declared a quarterly dividend. Jefferies highlighted DTE's increasing data center agreements and supportive regulatory environment as factors reducing business risk and boosting long-term growth. The company's investment narrative centers on translating data center demand into regulated earnings, though environmental concerns and potential regulatory pushback on rate hikes remain areas for investor scrutiny.

Baird has maintained its Outperform rating on Cardinal Health (CAH), despite lowering its price recommendation to $248 from $257, based on model updates after the company's first-quarter results and a raised 2027 forecast. BofA also reduced its price target to $240 from $260 but kept a Buy rating, noting Cardinal Health's mixed-to-positive fiscal Q3 results and increased fiscal 2026 EPS guidance. Cardinal Health raised its full-year fiscal 2026 non-GAAP EPS guidance to $10.70-$10.80 and adjusted free cash flow guidance to $3.3-$3.7 billion, while lowering its effective tax rate outlook.

A historic Coca-Cola plant in Ventura, California, which has operated for 114 years, is set to close permanently on July 10. Reyes Coca-Cola Bottling announced the closure, affecting 85 employees, most of whom are expected to be reassigned to other Southern California locations. This shutdown is part of a broader consolidation effort by the company and marks the end of one of Ventura's oldest industrial operations.

Indie Semiconductor President Ichiro Aoki sold 50,000 shares of Class A Common Stock for $238,795 on May 11, 2026, as part of a pre-arranged trading plan. Despite the sale, Aoki still holds significant shares and convertible units. This transaction follows the company's recent Q1 2026 earnings report and an acquisition announcement.

This article analyzes the price dynamics and execution-aware positioning for Aptus International Enhanced Yield ETF (NASDAQ: IDUB), noting a near-term neutral sentiment amidst mid and long-term strength. It highlights a critical resistance test and an exceptional short setup with a 12.6:1 risk-reward ratio. The analysis provides specific institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging with defined entry, target, and stop-loss levels.

A recent incident on a Delta Air Lines flight, where a passenger's reclined seat led to a "temper tantrum" from the person behind them, has sparked renewed debate about airline etiquette and "cost-cutting" measures. Many passengers are now blaming Delta, suggesting the carrier can "do better" instead of "squeezing in more passengers like sardines." Critics point to reduced legroom and "shrinkflation" tactics as part of a strategy to push premium seat sales, contrasting sharply with increased profits and CEO compensation.

Jack in the Box Inc. (NASDAQ: JACK) has announced a leadership change, appointing Mark King as Executive Chairman and Interim Chief Executive Officer. King, who has been a Board member since November 2025 and Chair since March 2026, replaces Lance Tucker, and will focus on accelerating the company's transformation. Alan Smolinisky has been named Lead Independent Director.

Gilead Sciences will present new data at the EASL Congress 2026 for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) and bulevirtide in hepatitis delta virus (HDV). The presentations will include late-breaking findings on Livdelzi's efficacy and safety across various PBC patient populations and interim data from ongoing studies. Additionally, Gilead will showcase advancements in HDV treatment and research in hepatitis B and C, reinforcing its commitment to addressing chronic liver diseases.

Eneos Holdings announced its plan to acquire Chevron's 50% stake in Singapore Refining Company (SRC) and other assets across Southeast Asia and Australia for $2.2 billion. This strategic move marks Eneos's first venture into Asia's refining business outside Japan and is expected to strengthen its business platform connecting Japan, Southeast Asia, and Oceania. The deal is anticipated to finalize in 2027.